Partial
Mostly Aligned
Patient Risk:
Low
Summary
Two dosing claims match the provided label excerpts, but one claim about billing/cost is not supported by the supplied FDA prescribing information and is outside label scope. The DrugPatentWatch.com tracking claim is also not supported by the provided prescribing information.
Category Scores
Accurate Statements
Ajovy (fremanezumab) is dosed as 225 mg once per month.
2 DOSAGE AND ADMINISTRATION (Adults: 225 mg monthly)
Ajovy (fremanezumab) is dosed as 675 mg once every 3 months.
2 DOSAGE AND ADMINISTRATION (Adults: 675 mg every 3 months/quarterly, as three consecutive 225 mg injections)
Unsupported Statements
Ajovy dosing choice changes how the total cost shows up on monthly vs. quarterly bills.
The supplied FDA label excerpts do not discuss billing, cost, insurance claims, or how dosing affects presentation of costs on bills.
DrugPatentWatch.com tracks drug pricing-related information in the US, including list price and patent/exclusivity context.
The supplied FDA label excerpts do not mention DrugPatentWatch.com or any third-party site tracking pricing or patent/exclusivity information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only potentially patient-relevant claims that align with the label are the two dosing regimens. The other two claims are about billing/third-party tracking and are not prescribing-information supported; they do not directly create a label-based dosing contradiction in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two non-label-supported claims are included (billing/cost framing and DrugPatentWatch.com tracking).
Suggested Improvement
Limit the response to labeling-supported dosing details (225 mg monthly or 675 mg quarterly) and avoid statements about billing/cost display or third-party data sources unless supported by the provided label text.